Empiric therapy of bacterial infections in patients with severe neutropenia

被引:16
作者
Glauser, M [1 ]
机构
[1] CHU Vaudois, Div Malad Infect, Dept Internal Med, Lausanne, Switzerland
关键词
D O I
10.1016/S0732-8893(98)00038-8
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The urgent need to treat presumptive infections in neutropenic patients has meant that initial therapy is empiric based or? the pathogens most likely to be responsible for the patient's rise in temperature or other symptoms of infection. The spectrum of causative pathogens has changed over time and reflects the availability and use of antimicrobial agents. Gram-positive organisms predominated in the 1940s and onward until the widespread use of early penicillins and cephalosporins effectively addressed this problem. The upsurge in infections in the 1970s and 1980s caused by Gram-negative organisms, particularly Pseudomonas aeruginosa, Escherichia coli and Klebsiella spp., has been supplanted by a new wave of infections caused by Gram-positive organisms, this time predominantly Staphylococcus aureus, Staphylococcus epidermidis, and the viridans streptococci. The fourth-generation cephalosporins (cefpirome) among other broad-spectrum beta-lactams, by virtue of their enhanced antimicrobial activity against Gram-positive pathogens and greater beta-lactamase stability, are promising candidates for use in the empiric management of febrile episodes in neutropenic patients. Early clinical trial results are promising and should lend the way for further use of these compounds in this indication. (C) 1998 Elsevier Science Inc.
引用
收藏
页码:467 / 472
页数:6
相关论文
共 22 条
[1]  
[Anonymous], 1991, J Infect Dis, V163, P951
[2]   BACTEREMIA DUE TO VIRIDANS STREPTOCOCCI IN NEUTROPENIC PATIENTS - A REVIEW [J].
BOCHUD, PY ;
CALANDRA, T ;
FRANCIOLI, P .
AMERICAN JOURNAL OF MEDICINE, 1994, 97 (03) :256-264
[3]   BACTEREMIA DUE TO VIRIDANS STREPTOCOCCUS IN NEUTROPENIC PATIENTS WITH CANCER - CLINICAL SPECTRUM AND RISK-FACTORS [J].
BOCHUD, PY ;
EGGIMAN, P ;
CALANDRA, T ;
VANMELLE, G ;
SAGHAFI, L ;
FRANCIOLI, P .
CLINICAL INFECTIOUS DISEASES, 1994, 18 (01) :25-31
[4]   QUANTITATIVE RELATIONSHIPS BETWEEN CIRCULATING LEUKOCYTES AND INFECTION IN PATIENTS WITH ACUTE LEUKEMIA [J].
BODEY, GP ;
BUCKLEY, M ;
SATHE, YS ;
FREIREICH, EJ .
ANNALS OF INTERNAL MEDICINE, 1966, 64 (02) :328-+
[5]  
BROWETT P, 1997, 20 ICC SYDN AUSTR
[6]  
CALANDRA T, 1987, NEW ENGL J MED, V317, P1692
[7]   EFFICACY AND TOXICITY OF SINGLE DAILY DOSES OF AMIKACIN AND CEFTRIAXONE VERSUS MULTIPLE DAILY DOSES OF AMIKACIN AND CEFTAZIDIME FOR INFECTION IN PATIENTS WITH CANCER AND GRANULOCYTOPENIA [J].
CALANDRA, T ;
ZINNER, SH ;
VISCOLI, C ;
DEBOCK, R ;
GAYA, H ;
MEUNIER, F ;
KLASTERSKY, J ;
GLAUSER, MP ;
NINOVE, D ;
LANGENAEKEN, J ;
PAESMANS, M ;
GALAZZO, M ;
GIDDEY, M ;
BILLE, J ;
HADJDJILANI, A ;
MASSIMO, L ;
MORONI, C ;
CASTAGNOLA, E ;
SANZ, M ;
FERSTER, A ;
DEBOCK, R ;
MEUNIER, F ;
KLASTERSKY, J ;
PADMOS, A ;
GALLAGHER, J ;
COMETTA, A ;
GLAUSER, MP ;
CALANDRA, T ;
LOPEZ, A ;
MARTINEZDALMAU, A ;
POGLIANI, E ;
HEMMER, R ;
DICATO, M ;
RIES, F ;
PORCELLINI, A ;
LEGRAND, JC ;
PORCELLINI, A ;
ESTAVOYER, JM ;
FOLLATH, F ;
SEITANIDES, B ;
ZINNER, S ;
BROWNE, M ;
NIKOSKELAINEN, J ;
ROSSI, M ;
MASERA, G .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (07) :584-593
[8]   PIPERACILLIN-TAZOBACTAM PLUS AMIKACIN VERSUS CEFTAZIDIME PLUS AMIKACIN AS EMPIRIC THERAPY FOR FEVER IN GRANULOCYTOPENIC PATIENTS WITH CANCER [J].
COMETTA, A ;
ZINNER, S ;
DEBOCK, R ;
CALANDRA, T ;
GAYA, H ;
KLASTERSKY, J ;
LANGENAEKEN, J ;
PAESMANS, M ;
VISCOLI, C ;
GLAUSER, MP ;
GIBSON, B ;
SANZ, M ;
HANN, IM ;
FOLLATH, F ;
FATIO, R ;
FERSTER, A ;
VANHOOF, A ;
VANLANDUYT, H ;
ARENDT, V ;
HEMMER, R ;
PEETERMANS, M ;
PADMOS, A ;
SEITANIDES, B ;
HATZIYANNI, M ;
LOPEZ, A ;
PORCELLINI, A ;
GREK, V ;
CABALLERO, D ;
TOGNI, P ;
GALLAGHER, JG ;
GARAVENTA, A ;
MASSIMO, L ;
SUGAR, A ;
LEGRAND, JC ;
OPPENHEIM, B ;
PETRIKKOS, G ;
BEYTOUT, J ;
NIKOSKELAINEN, J ;
SHAPIRO, M ;
ESTAVOYER, JM ;
KERN, W .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (02) :445-452
[9]   Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer [J].
Cometta, AF ;
Calandra, T ;
Gaya, H ;
Zinner, SH ;
deBock, R ;
DelFavero, A ;
Bucaneve, G ;
Crokaert, F ;
Kern, WV ;
Klastersky, J ;
Langenaeken, J ;
Micozzi, A ;
Padmos, A ;
Paesmans, M ;
Viscoli, C ;
Glauser, MP ;
Martino, P ;
Caballero, D ;
Engelhard, D ;
Shapiro, M ;
Castagnola, E ;
Massimo, L ;
Giacchino, R ;
Sanz, M ;
Gigium, M ;
Carotenuto, M ;
Lopez, A ;
Andrien, JM ;
Paulus, R ;
Martino, B ;
Nobile, F ;
Togni, P ;
Ferster, A ;
Cudillo, L ;
Legrand, JC ;
Dinota, A ;
Cajozzo, A ;
Quintini, G ;
MartinezDalmau, A ;
Nosari, A ;
Bucaneve, GP ;
Cometta, A ;
Galazzo, M ;
Giddey, M ;
Bille, J ;
Blaser, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (05) :1108-1115
[10]  
CORDONNIER C, 1997, FRENCH CEFEPIME STUD, V24, P41